FDA Approves Oral Testosterone Replacement Therapy Kyzatrex
Kyzatrex is a Schedule III controlled substance.
Source: renalandurologynews.com
Stay updated with breaking news from Accessed August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kyzatrex is a Schedule III controlled substance.
The FDA has approved Cimerli (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab).
The FDA has approved Stelara (ustekinumab) to treat pediatric patients 6 years of age and older with active psoriatic arthritis.
The FDA has accepted for Priority Review the sNDA for ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis.